Abstract
The treatment of malignant brain tumors remains a challenge. Stem cell technology has been applied in the treatment of brain tumors largely because of the ability of some stem cells to infiltrate into regions within the brain where tumor cells migrate as shown in preclinical studies. However, not all of these efforts can translate in the effective treatment that improves the quality of life for pa-tients. Here, we perform a literature review to identify the problems in the field. Given the lack of efficacy of most stem cell-based agents used in the treatment of malignant brain tumors, we found that stem cell distribution (i.e. , only a fraction of stem cells applied capable of targeting tumors) are among the limiting factors. We provide guidelines for potential improvements in stem cell distribution. Specifically, we use an engineered tissue graft platform that replicates the in vivo microenvironment, and provide our data to validate that this culture platform is viable for producing stem cells that have better stem cell distribution than with the Petri dish culture system.
INTRODUCTION

Malignant brain tumors are devastating to patients Billions of dollars have been spent since United States
President Richard Nixon declared the "war on cancer." Understanding the molecular biology of cancer led to gain better survival in certain cancers, such as childhood leukemia. However, survival in solid tumors has not improved since the 1970s. New studies revealed that unexpected factors such as intratumoral heterogeneity [1] and clonal evolution force us to realize that classical therapies cannot fully address the tumor subclonal switch mechanism that allow tumors to escape therapy [2] . This includes chemotherapy drug temozolomide-driven evolution of recurrent glioma [3] into a restricted subclonal cell population of drug-resistance [4] . Ineffective cancer treatment results in mortality and economic burden: one-third of 2007 healthcare dollars (total: $686 billion) was spent on 1.4 million cancer patients in the United States [5] [6] [7] . Some pediatric malignant brain tumor patient costs $67887, which is 200 times as much as a demographical control, $277 [5, 8] . It is devastating, considering that the fortunate survivors suffer cognitive changes, cognitive deficiency that challenges the quality of life of both patients and their care givers [9] .
LIMITATION OF CURRENT STANDARD TREATMENT
Cancer treatment is largely unsuccessful due to current blindfolded anti-cancer strategic and tactical issues in the fight. Surgical resection allows glioma patients survive the traumatic attack; however, surgery alone cannot clear the residual infiltrative glioma. Malignant brain tumors disseminate widely to distant regions of normally functioning tissues [10] . Thus, surgery in conjunction with chemotherapy and radiation therapy still cannot eradicate residual tumors [11, 12] .
ADVERSE SIDE EFFECTS OF STANDARD
THERAPIES
Chemotherapy and radiation therapy do not strictly discriminate tumor cells from normal cells, resulting in adverse effects. Survivors of current standard brain tumor treatment show neurological, cognitive, endocrine sequelae, and metabolic side effects [11, [13] [14] [15] [16] [17] [18] [19] [20] . These side effects result from the cumulative effects of pre-treatment injury caused by the growing tumor, the adverse impact of surgery and from adjuvant therapeutics (chemotherapy and radiation therapy) [21] . The surgical removal of the initial tumor followed with adjuvants (radiation plus chemotherapy) may awaken the dormant clones of the primary tumor and these cells then grow to form a secondary tumor ( Figure 1 ) as the dormant cells go through switchboard signaling to become dominate clones of cancer [2] . These glioma residues grow back, leading to recurrent incurable and metastatic cancer. Adjuvant therapies (Local radiotherapy, chemical sensitizers, gene therapy) did not provide any survival advantage in clinical trials.
GENETIC PROFILING
Genetic profiling shows the potential genetic risk factors for patients and a way to predict how a patient may react with a given tumor treatment. Across 12 tumor types in 2928 out of 3277 patients, The Cancer Genome Atlas Network (TCGA) analyzed 10281 somatic alterations [22] . This TCGA data set predicts patient survival when applying therapies useful in one cancer type to other cancer types. This molecular profile-based prediction of therapeutic efficacy may imply a new classification system different from the previous organ-based tumor classification system [23] .
For example, the analysis of somatic mutations in glioblastoma multiforme (GBM) [24] helped establish Proneural, Neural, Classical, and Mesenchymal subtypes [24] . Each subtype, with its own molecular stratification (PDG-FRA, IDH1, EGFR, and NF1 gene), can exhibit specific drug targets that minimize adverse effects and enhance efficacy. Another study shows that recurrent H3F3A mutations are further characterized into six methylation patterns [25] . The methylation patterns help design epigeneticpattern-specific targeted therapies [25] . Molecular changes in BRAF, RAF1, FGFR1, MYB, MYBL1, H3F3A, and ATRX were identified in 151 low-grade gliomas (LGGs) [26] . Another study defined recurrent activating mutations in FGFR1, PTPN11, and NTRK2 genes in
LGGs [27] . The mutations imply some targeted therapies, e.g., specific inhibitors against FGFR1 autophosphorylation can block MAPK/ERK/PI3K, preventing cancer cells from proliferating. These mutations can help focus targeted therapies for patients. Temozolomide (TMZ) and radiation, increase survival for patients with Classical or Mesenchymal subtypes but not with Proneural subtype [24] . However, chemotherapy can activate chemoresistent cancer cells. TMZ drives a subset of endogenous cells out of their quiescent subventricular zone to develop to a new tumor [4] . Evidence shows that TP53, ATRX, SMARCA4, and BRAF mutations in the initial tumor but were undetected at recurrence, suggesting new mutations occur upon drugdriven tumor evolution. TMZ-activated RB (retinoblastoma) and Akt-mTOR (mammalian target of rapamycin) mutations led to recurrent tumors [3] . New strategy to address these therapy-driven detrimental effects in a realtime manner is needed.
EMERGING THERAPIES
Neural stem cells (NSCs) possess the tumor-tracking capacity as shown in preclinical models [28] . NSCs modulate the brain tumor microenvironment [29] [30] [31] [32] . Other candidate stem cells include HSCs [33] , BM-MSC [34] , and induced pluripotent stem cells (iPSC) [35] . Because iPSC technology enables autologous transplantation allowing immune compatibility with a host immune system (Figure 2 ), iPSCs are proposed for replacement therapy in certain diseases [36] . However, potential immune rejection of these autologous iPSCs remains to be tested in clinical trials [37] . These stem cells could be engineered as delivery vehicles for therapeutic agents [38] such as antibody [39] , oncolytic adenoviral virotherapy [40] , and prodrug therapy [41] . NSCs inhibit glioma proliferation in vivo and in vitro [42] . Intracranial tumors activate endogenous NSCs to migrate towards neoplastic target lesions [43, 44] .
Evidence shows that BM-MSCs work in the same fashion as NSCs [34] . MSCs exhibit tropism towards gliomas [45] [46] [47] ). MSCs locally produce IFN-β that suppresses cancer cells [48] .
CLINICAL TRIALS SHOW
DISCREPANCIES
Serving to reconstitute hematopoietic and immune function, some stem cells act as a salvage therapy for surgery, radiation therapy, and high dose chemotherapy. For example, patients rely on autologous hematopoietic stem cell transplantation to replenish immune capacity against recurrent cancer after surgery and chemotherapy [49] . Currently, 240 studies on "stem cell therapy of cancer" exist in mostly Phases and specificity; and (3) The vehicle possesses the ability to home in on targets.
Stem cell therapy provides the essential components of such a defined therapeutic agent, as fellows.
The therapeutic agent: Therapeutic benefits of stem cells include (1) regenerative action; (2) neuroprotective modulation; and (3) immune regulation. The BM-MSC transplantation induces survival and proliferation of host neurons through secreting BDNF, β-NGF, and adhesion molecules [50] . Stem cells can serve as a "Trojan Horse" for transplantation of cancer drugs [50, 51] .
The autopilot vehicle: NSCs can detect a target (homing) via chemokines produced by tumors (Figure 4 , Li et al [7] 2008), the capacity like a self-driving vehicle. Following this chemokine gradient, NSCs can move through tissue barriers such as the blood brain barrier and brain tumor barrier ( Figure 3 ) to reach their target tissue. We need to determine the therapeutic window of stem cell development, the window of stem cell development that is capable for targeting tumors [52] . If stem cells develop outside of a window period, thereby lose the ability of migrating toward tumors because their migrationrequired molecules are down regulated [53] .
Delivery system: Stem cell delivery for cancer remains to be defined. For brain tumors, we can use a stereotactic injection for a specific brain region. Mooney and colleagues show that NSCs can facilitate the tumor-selective distribution of nanoparticles, a drug-loading system that is promising in cancer therapy [54] . We can apply CED (convection-enhanced delivery) to deliver stem cells across the blood-brain barrier and the brain-tumor barrier ( Figure 3 ). We need further to track down stem cell migration in vivo by using a real-time tracking system as we discussed previously [55] , a way that can address possible adverse effects. the conventional HSC transplantation. Phase I trials using tumor dendritic vaccines evaluated the side effects of vaccine therapy on recurrent GBM (ClinicalTrials.gov Identifier: NCT00890032 -tumor cells/dendritic cells; ClinicalTrials.gov Identifier: NCT01171469-tumor stem cells; assessed on August 22, 2014), a potential that a realtime anti-cancer system is established in vivo to monitor cancer growth. These everlasting vaccines are expected to set up an immune response to stop cancer.
Discrepancies of efficacy occurred in all these clinical trials and efforts have been made to explain what roadblocks are in the way for achieving consistent efficacy. Roadblocks for stem cells to reach the site of the tumor include the blood brain barrier (BBB) and the brain tumor barrier (BTB) (Figure 3 ). Most intravenously administered NSCs cannot cross BBB and BTB but only a few do [7] . These roadblocks must be removed to clear that path for success of stem cell therapy for cancer [7] . Specifically, we need to cultivate potentiated stem cells to be potent to tranverse these roadblocks.
THE NEED TO FIND WAYS OF IMPROVING THE POTENCY OF STEM CELLS
What qualities for stem cells could allow therapeutic effectiveness? The ideal stem cells should provide: (1) longdistance inter-organ autopilot traveling to surgically inaccessible tumors, ideally when administrated by peripheral intravenous injection; (2) accuracy in eliminating tumors without adversely affecting normal organs; (3) capability of suppressing primary and metastatic tumor; and (4) memory so that recurrence never occurs. (1) The therapeutic agent shows the maximum anti-cancer efficacy with the minimum adverse effect; (2) The vehicle should protect the therapeutic agent for its potency Figure 3 Convection enhanced delivery of therapy to overcome two barriers of brain tumors. A: Systemic delivery of drugs blocked from entry into the brain by the blood brain barrier; B: Drug delivery inhibited by the brain-tumor barrier. This convection enhanced delivery can be used to deliver neural stem cells locally onto a tumor.
Components of an inter-organ movable vehicle for targeting cancer
A PROBLEM IN STEM CELL TRANSPLANTATION AND ITS SOLUTION
Only marginal effects can be observed in stem cell therapy despite exciting potency shown in some animal models [52] . In fact, it is a game of number wrestling between good stem cells and tumor cells [52, 53] . Current stem cell experiments in mouse models involve transplantation of millions of stem cells, with only some migrating toward tumors, a few surviving at the tumor site, and rare engraftment [52, 53] . The rest of the non-migratory stem cells are detrimental to a recipient, because these can induce the formation of heterogeneous tumor and inflammation. Thus, we must enable stem cells to pass certain uniform quality control standard so that they can fulfill their designed purpose of targeting brain tumors.
TRAIN STEM CELLS IN AN ORGAN-
SPECIFIC MICROENVIRONMENT
The low number of stem cells capable of migrating toward tumors derived from Petri dish culture system as shown in preclinical and clinical studies may result from the following differences: (1) the source of stem cells; (2) methods of stem cell culture; (3) differentiation status (percentage of differentiated cells); (4) the age of the stem cells in culture; and (5) the nature of a tumor [34] . We found that culture matrix makes a difference in stem cell characteristics. NSCs behave differently in coated Petri culture plates ( Figure 5 ). NSCs show much more neurite growth on Matrigel-coated Petri polystyrene plates than on other adhesion molecule-coated plates (Collagen Ⅰ, Collagen Ⅳ, or Laminine). Nevertheless, none of these adhesion molecules can generate uniform populations of stem cells. We have designed an engineered tissue graft model as a universal training platform to address the issue of heterogeneity of cultured stem cells [7] . An engineered tissue graft (ETG) provides a native organ microenvironment closer to an in vivo model and very different from an in vitro Petri dish (polystyrene plates) system (Figure 4) [56] . This ETG model can be generated from patient specific brain tumor specimens for autologous characterization of therapeutic in vivo-like trials of a new drug ( Figure 6 ). This ETG material was made according to our patented technology -an ETG generated by seeding brain tumor stem cells onto slice cultures of patients' pathological brain tissue harvested during tumor resection -which preserved the pathological micro-environment [52] .
Such a culture platform can train stem cells to fulfill the purpose of targeting brain tumor cells as they help generate uniform neurite formation in culture that is essential for brain-tumor-targeted migration (Figure 7) . These ETG-based matrix produced cells express molecu- lar markers different from cells cultured on polystyrene plates (PS) as shown in gene arrays (Figure 8 ). We can obtain a morphologically uniform population of stem cells in an ETG microenvironment (Figure 9 ). Optimizing the chemokine responsiveness (chemokine receptors expressed by stem cells) and upregulating matrix-remodeling matrix metalloproteinases (MMPs) are essential: Both chemokine receptor and MMPs are well expressed in cells with ETG but not with Petri dish culture system [7] . Additionally, to overcome the problem of immune response, we have designed autologous iPSCs (induced pluripotent stem cells) for certain patient tumors (Figure 3 ), a dual system that can mutually promote each other for better efficacy. These trained stem cells can act as an autopilot vehicle that is self-driven to its target (Li et al [7] , 2008, Figure 5 ). This ETG can be engineered to mimic the in vivo fluidic microenvironment with the continuous flow of physicochemical buffer, the microfluidic system that can be coupled with real-time imaging for analysis of cell development as the quality control (QC) as detailed in a recent report [57] . In the future, a QC system should be implemented for the structural and functional characterization of stem cell production before using for transplantation. This ETG could be scaled for automatic studies.
CONCLUSION
Stem cell therapies of brain tumors are being investigated preclinically; however, little efficacy has been found in clinical trials. We reviewed the literature and found that heterogeneous stem cell populations were made using artificial matrices, a roadblock to achieve consistent efficacy. We provide an ETG as a uniform platform to train stem cells for attacking tumor cells, which may address the discrepancies of current clinical trials. 
